Clinical trials: Dementia Mild
Alzheimer's Disease
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARBEAM (NCT02006641)
- Testing
- Idalopirdine
- Where
- 162 sites in United States, Argentina and 17 more
- Volunteers
- 858 people
- Sponsor
- H. Lundbeck A/S
Subjective Cognitive Decline, Alzheimer Disease
Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns
AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.
- Conditions
- Subjective Cognitive Decline, Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- AHEAD (NCT07652931)
- Testing
- High-frequency Transcranial Magnetic Stimulation (TMS), Digital Cognitive Training, Structured Physical Exercise
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS San Raffaele
Neurological Diseases or Conditions, Dementia of Alzheimer Type
An Observational Study of Patients Living With Chronic Neurological Diseases
TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment…
- Conditions
- Neurological Diseases or Conditions, Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT05796037
- Volunteers
- 1,500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Alzheimer's Disease
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00454870
- Testing
- MEM 3454
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memory Pharmaceuticals
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Alzheimer Disease
- Trial name
- MESO7 (NCT07202494)
- Testing
- Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)
- Where
- France
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Alzheimer Disease, Mild Cognitive Impairment
Disclosing Dementia Risk Based on Plasma Phosphorylated Tau
Novel blood-based biomarkers of Alzheimer's disease (AD), such as plasma levels of tau phosphorylated at threonine 181 (p-tau181), have shown great promise in detecting early AD pathology.
- Trial name
- NCT05377060
- Testing
- Plasma p-tau risk disclosure, Standard risk disclosure
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt University Medical Center
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer Disease, Mild Cognitive Impairment
A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking
This is a longitudinal, observational study evaluating the imaging characteristics of the tau PET radioligand [18F]MK-6240 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and Healthy Volunteer (HV) subjects.
- Trial name
- NCT03919669
- Testing
- All Subjects
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Dementia, Dementia, Vascular
PUMCH Dementia Longitudinal Cohort Study
The PUMCH Dementia Cohort is a hospital-based, observational study of Chinese elderly with cognitive impairment.
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia, Mixed
- Trial name
- NCT05023564
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Dementia, Mild, Mild Cognitive Impairment
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and…
- Conditions
- Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
- Trial name
- NCT07083154
- Testing
- Mazdutide
- Where
- 8 sites in China
- Volunteers
- 420 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Depression, Anxiety
CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia
Age remains the single most significant risk factor for developing dementia, particularly Alzheimer's dementia (AD). Given the rate at which Canada's population is aging, the quest to determine modifiable risk factors, whether by…
- Conditions
- Depression, Anxiety, Mild Cognitive Impairment
- Trial name
- CCI (NCT02955719)
- Testing
- Sertraline, Venlafaxine, CBT/Psychological Therapy
- Where
- Canada
- Volunteers
- 145 people
- Sponsor
- Centre for Addiction and Mental Health
Intact Cognitive Function, MCI
Developing and Testing an AI-Based Cognitive Intervention Program
The goal of this clinical study is to learn if an artificial intelligence (AI)-assisted lifestyle intervention program can help protect memory and thinking skills in adults aged 40 years and older who do not have severe cognitive…
- Conditions
- Intact Cognitive Function, MCI, Mild Dementia
- Trial name
- AICog (NCT07766993)
- Testing
- Lifestyle Intervention
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Research Center for Rehabilitation Technical Aids
Alzheimer Disease
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, plus QS-21 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00960531
- Testing
- ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
- Where
- 28 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimer's Disease
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
Primary Objective: To assess the safety and tolerability of escalating single and multiple doses of SAR228810 in patients with Alzheimer's disease (AD) Secondary Objective: To evaluate the pharmacokinetic properties of SAR228810…
- Trial name
- NCT01485302
- Testing
- SAR228810
- Where
- 8 sites in Bulgaria, France and 3 more
- Volunteers
- 48 people
- Sponsor
- Sanofi
Dementia, tDCS
The Efficacy of HD-tDCS-Augmented Step Training in Older Adults With Mild Dementia
Falls and mobility decline are major health concerns among older adults with dementia, often linked to deterioration in executive function and cognitive-motor control.
- Conditions
- Dementia, tDCS, Physical Exercise, Neuromodulation
- Trial name
- NCT07841145
- Testing
- Step training, active HD-tDCS
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- The Hong Kong Polytechnic University
Mild Cognitive Impairment, Alzheimer's Disease
Investigating the Clinical Consequences of Flutemetamol-PET-scanning
The study examines subjects where there might be an indication for Amyloid-PET according to the Criteria defined by the Amyloid Imaging Task Force.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Dementia
- Trial name
- NCT02353949
- Testing
- Flutemetamol (Vizamyl)
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- University of Zurich
Alzheimer´s Disease
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD).
- Trial name
- AD Biomarker (NCT07741526)
- Testing
- NPI-001
- Where
- 4 sites in Denmark, Iceland
- Volunteers
- 33 people
- Sponsor
- Arctic Therapeutics
Alzheimer's Disease, Mild Cognitive Impairment
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose study of ABT-957 in participants with mild Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) due to AD.
- Trial name
- NCT02573740
- Testing
- ABT-957
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- AbbVie
Alzheimer Disease, Mild Cognitive Impairment
Reversal of Cognitive Decline (ReCODE) Study
Prospective study on patients enrolled in the ReCODE treatment protocol
- Trial name
- RECODE (NCT03883633)
- Testing
- ReCODE Protocol
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- QuesGen Systems Inc
Huntington Disease, Chorea
Atomoxetine and Huntington's Disease
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements…
- Trial name
- NCT00368849
- Testing
- atomoxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa